Correction

Can We Decide Which Outcomes Should Be Measured in Every Clinical Trial? A Scoping Review of the Existing Conceptual Frameworks and Processes to Develop Core Outcome Sets

Idzerda L, Rader T, Tugwell P, Boers M. Can we decide which outcomes should be measured in every clinical trial? A scoping review of the existing conceptual frameworks and processes to develop core outcome sets. J Rheumatol 2014;41:986-93; published online before print: doi:10.3899/jrheum.131308

In the scoping review of processes used to develop core sets[1], the summary of the work done in eczema (Table 3) was incomplete, listing only the initial systematic review. Briefly, the Harmonising Outcome Measures for Eczema (HOME) initiative[2] is an international multiprofessional group that aims to standardize and validate a core set of outcome measurement instruments for atopic eczema. Following a systematic review[3] on the domains and instruments to measure aspects of severity of eczema, a multiperspective consensus panel was established consisting of patient representatives, clinicians, journal editors, and regulators to define a core set of outcome domains for eczema trials and for record keeping in routine care[4]. Delphi methods and nominal group technique have been used in the development process[5]. HOME has been linked with Outcome Measures in Rheumatology Clinical Trials (OMERACT) from the beginning, and is applying the OMERACT filter[6] as a criterion to recommend outcome measurement instruments[7].

We regret the omission.

REFERENCES

1. Idzerda L, Rader T, Tugwell P, Boers M. Can we decide which outcomes should be measured in every clinical trial? Systematic review of concepts and methodologies used to establish core sets for outcome measurement. J Rheumatol 2014;41:986-93.
2. Schmitt J, Williams HC. Harmonising outcome measures for eczema (HOME). Report from the first international consensus meeting (HOME 1), 24 July 2010, Munich, Germany. Br J Dermatol 2010;163:1166-8.
3. Schmitt J, Langan SM, Williams HC. What are the best outcome measurements for atopic eczema? A systematic review. J Allergy Clin Immunol 2007;120:1389-98.
4. Schmitt J, Langan S, Stamm T, Williams HC; Harmonizing Outcome Measurements in Eczema (HOME) Delphi panel. Core outcome domains for controlled trials and clinical recordkeeping in eczema: international multiperspective Delphi consensus process. J Invest Dermatol 2011;131:623-30.
5. Schmitt J, Spuls P, Boers M, Thomas K, Chalmers J, Roekevisch E, et al. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. Allergy 2012;67:1111-7.
6. Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol 1998;25:198-9.
7. Schmitt J, Langan S, Deckert S, Svensson A, von Kobyletzki L, Thomas K, et al. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol 2013;132:1337-47.

doi:10.3899/jrheum.131308.C1

Downloaded on April 24, 2024 from www.jrheum.org